Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate

Eur J Cancer Clin Oncol. 1987 May;23(5):481-5. doi: 10.1016/0277-5379(87)90307-5.

Abstract

Methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) plasma concentration-time curves (AUC) have been analyzed in 24 patients after different routes of MTX administration. After an i.v. bolus (50 mg/m2), the AUC for 7-OH-MTX is correlated with that for MTX and inversely correlated with the MTX plasma clearance. When MTX is administered with plasma steady level standardization, using the test-dose protocol, at a level of 10(-5) M over 36 hr (10(-5), 36 hr), 7-OH-MTX-AUC is still correlated with the i.v. bolus pharmacokinetic parameters. The dose prediction using the classical test-dose protocol provides a less efficient MTX dose adjustment at 5 X 10(-4) M over 8 hr (5.10(-4), 8 hr) and the hydroxylation process is no more correlated with the i.v. parameters. On the opposite, upon 6 successive infusions with 10(-5), 36 hr or 5.10(-4), 8 hr protocols, the plasma concentrations of 7-OH-MTX are not significantly modified. This suggests that the hydroxylation process is not inducible.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / metabolism
  • Humans
  • Hydroxylation
  • Infusions, Intravenous
  • Injections, Intravenous
  • Methotrexate / administration & dosage*
  • Methotrexate / analogs & derivatives*
  • Methotrexate / blood
  • Methotrexate / pharmacokinetics
  • Middle Aged
  • Osteosarcoma / drug therapy
  • Osteosarcoma / metabolism

Substances

  • 7-hydroxymethotrexate
  • Methotrexate